All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Oncology Drugs in Phase II/III Clinical Development in GERMANY

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

MorphoSys

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

Contact the Supplier

Lead Product(s): Tafasitamab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Incyte Corporation

Deal Size: $2,000.0 million Upfront Cash: $750.0 million

Deal Type: Collaboration January 13, 2020

Details:

MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S.